This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gales, A.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gales, A.
Right arrow Articles by Jones, R. N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2001, p. 1463-1466, Vol. 45, No. 5
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.5.1463-1466.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae Isolates from SENTRY Antimicrobial Surveillance Program Medical Centers in Latin America (1999)

SENTRY Participants Group (Latin America),dagger Ana Gales, Helio Sader, and Ronald N. Jones*

University of Iowa College of Medicine, Iowa City, Iowa

Received 14 August 2000/Returned for modification 1 February 2001/Accepted 21 February 2001

The antimicrobial activity of BMS 284756, a novel des-F(6)-quinolone, was comparatively evaluated against 257 Streptococcus pneumoniae, 198 Haemophilus influenzae, and 88 Moraxella catarrhalis strains isolated in Latin America between July and September of 1999 as part of the SENTRY Antimicrobial Surveillance Program. Nearly 28.0% of S. pneumoniae strains were nonsusceptible to penicillin. The rank order of quinolone potency versus S. pneumoniae was BMS 284756 (MIC at which 90% of isolates were inhibited [MIC90], 0.12 µg/ml) > trovafloxacin (MIC90, 0.25 µg/ml) > gatifloxacin (MIC90, 0.5 µg/ml) > levofloxacin and ciprofloxacin (MIC90, 1 to 2 µg/ml). All S. pneumoniae strains that were not susceptible to other quinolones were inhibited by BMS 284756 at <= 2 µg/ml. The overall prevalence of beta -lactamase production was 15.2% in H. influenzae and 98.9% in M. catarrhalis. BMS 284756 showed excellent potency and spectrum against this group of pathogens, inhibiting all isolates at <= 0.12 µg/ml. BMS 284756 exhibited activity similar to those displayed by the new fluoroquinolones, such as levofloxacin, trovafloxacin, or gatifloxacin, and could be a therapeutic option for empirical treatment of community-acquired respiratory tract infections.

* Corresponding author. Mailing address: The JONES Group, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317. Phone: (319) 665-3370. Fax: (319) 665-3371. E-mail: ronald-jones{at}jonesgr.com.

dagger Participants include the following: Laboratorio Santa Luzia (C. Zoccoli), Florianopolis, Brazil; Centro de Estudios en Antimicrobianos (J. M. Casellas), Buenos Aires, Argentina; Microbiology Laboratory C.E.M.I.C. (J. Smayevsky), Buenos Aires, Argentina; Unidad de Microbiologia Oriente (V. Prado), Santiago, Chile; Universidad Catolica (E. Palavecino), Santiago, Chile; Corp. Para Investig. Biologicas (J. A. Robledo), Medellin, Colombia; Instituto de Doenias Infecciousas-IDIPA (H. Sader), Sao Paulo, Brazil; Centro Medico de Caracas (M. Guzman), San Bernardino Caracas, Venezuela; Hospital Ageles Del Pedregal (J. M. Presno-Bernal), Mexico D.F, Mexico; and Hospital de Clinicas de Porto Alegre (A. L. Barth), Porto Alegre-RG, Brazil.

Antimicrobial Agents and Chemotherapy, May 2001, p. 1463-1466, Vol. 45, No. 5
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.5.1463-1466.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Christiansen, K. J., Bell, J. M., Turnidge, J. D., Jones, R. N. (2004). Antimicrobial Activities of Garenoxacin (BMS 284756) against Asia-Pacific Region Clinical Isolates from the SENTRY Program, 1999 to 2001. Antimicrob. Agents Chemother. 48: 2049-2055 [Abstract] [Full Text]  
  • Azoulay-Dupuis, E., Bedos, J. P., Mohler, J., Peytavin, G., Isturiz, R., Moine, P., Rieux, V., Cherbuliez, C., Pechere, J. C., Fantin, B., Kohler, T. (2004). Activities of Garenoxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model. Antimicrob. Agents Chemother. 48: 765-773 [Abstract] [Full Text]  
  • Gajjar, D. A., Bello, A., Ge, Z., Christopher, L., Grasela, D. M. (2003). Multiple-Dose Safety and Pharmacokinetics of Oral Garenoxacin in Healthy Subjects. Antimicrob. Agents Chemother. 47: 2256-2263 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»